Sio Gene Therapies (Sio Gene Therapies) EBIT : $-29.41 Mil (TTM As of Dec. 2022)

View and export this data going back to 2015. Start your Free Trial

What is Sio Gene Therapies EBIT?

Sio Gene Therapies's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2022 was $-4.48 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2022 was $-29.41 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Sio Gene Therapies's annualized ROC % for the quarter that ended in Dec. 2022 was -3,389.79%. Sio Gene Therapies's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2022 was -512,342.86%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Sio Gene Therapies's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2022 was 273.14%.

Sio Gene Therapies EBIT Historical Data

The historical data trend for Sio Gene Therapies's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sio Gene Therapies EBIT Chart

Sio Gene Therapies Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

EBIT

Get a 7-Day Free Trial

-213.11

-121.40

-67.81

-31.84

-71.60

Sio Gene Therapies Quarterly Data
	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
EBIT	Get a 7-Day Free Trial															-25.37	-13.12	-8.53	-3.28	-4.48

Competitive Comparison of Sio Gene Therapies's EBIT

For the Biotechnology subindustry, Sio Gene Therapies's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sio Gene Therapies's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sio Gene Therapies's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Sio Gene Therapies's EV-to-EBIT falls into.

Sio Gene Therapies EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-29.41 Mil.

Sio Gene Therapies (OTCPK:SIOX) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Sio Gene Therapies's annualized ROC % for the quarter that ended in Dec. 2022 is calculated as:

	ROC % (Q: Dec. 2022 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Sep. 2022 )	+	Invested Capital (Q: Dec. 2022 ))	/ count )
=	-17.932 * ( 1 - 0% )	/	( (0.486	+	0.572)	/ 2 )
=	-17.932	/	0.529
=	-3,389.79 %

where

	Invested Capital		(Q: Sep. 2022 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	53.746	-	4.355	-	( 49.865	-	max(0, 4.834	-	53.739	+	49.865	))
=	0.486

	Invested Capital		(Q: Dec. 2022 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	47.272	-	1.58	-	( 46.127	-	max(0, 2.152	-	47.272	+	46.127	))
=	0.572

Note: The Operating Income data used here is four times the quarterly (Dec. 2022) data.

2. Joel Greenblatt's definition of Return on Capital:

Sio Gene Therapies's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2022 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2022 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Sep. 2022		Q: Dec. 2022
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-17.932	/	( ( (0.007 + max(-1.311, 0))	+	(0 + max(-1.363, 0)) )	/	2 )
=	-17.932	/	( ( 0.007	+	0 )	/	2 )
=	-17.932	/	0.0035
=	-512,342.86 %

where Working Capital is:

	Working Capital		(Q: Sep. 2022 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	3.519)	-	(4.355	+	0	+	0.475)
=	-1.311

	Working Capital		(Q: Dec. 2022 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.78899999999999)	-	(1.58	+	0	+	0.572)
=	-1.363

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2022) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Sio Gene Therapies's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2022 )
	=	-29.409	/	-10.767
	=	273.14 %

Sio Gene Therapies EBIT Related Terms

Thank you for viewing the detailed overview of Sio Gene Therapies's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Sio Gene Therapies (Sio Gene Therapies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sio Gene Therapies Inc (OTCPK:SIOX) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

130 West 42nd Street, 26th Floor, New York, NY, USA, 10036

Website

https://www.siogtx.com

Sio Gene Therapies Inc is a clinical-stage company that is focused on gene therapy for neurodegenerative diseases. The company is developing its pipeline for the treatment of debilitating diseases, including Parkinson's disease, GM1 gangliosidosis, and GM2 gangliosidosis.

Executives

Parag V Meswani	officer: Chief Commercial Officer	130 WEST 42ND STREET, 26TH FLOOR, NEW YORK NY 10036
Pavan Cheruvu	officer: Chief Executive Officer	C/O AXOVANT SCIENCES, INC., 11 TIMES SQUARE, 33RD FLOOR, NEW YORK NY 10036
Atul Pande	director	C/O AXOVANT SCIENCES, INC., 1441 BROADWAY, 3RD FLOOR, NEW YORK NY 10018
Kristiina Md Vuori	director	C/O WEBMD HEALTH CORP., 111 EIGHTH AVENUE, NEW YORK NY 10011
Roivant Sciences Ltd.	10 percent owner	CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Eric Venker	director	C/O ROIVANT SCIENCES, INC., 320 WEST 37TH STREET, 6TH FLOOR, NEW YORK NY 10018
David W. Nassif	officer: Principal Financial Officer	C/O STEADYMED THERAPEUTICS, INC., 2410 CAMINO RAMON, SAN RAMON CA 94583
Senthil Vel Sundaram	director	NIGHTSTAR THERAPEUTICS PLC, 203 CRESCENT STREET, SUITE 303, WALTHAM MA 02453
Dexxon Holdings Ltd.	10 percent owner	1 DEXCEL STREET, OR AKIVA L3 30600000
Andrew Lo	10 percent owner	C/O ALPHASIMPLEX GROUP, LLC, ONE CAMBRIDGE CENTER, 9TH FLOOR, CAMBRIDGE MA 02142
Svf Investments (uk) Ltd	10 percent owner	69 GROSVENOR STREET, LONDON X0 W1K3JP
Patrick Machado	10 percent owner	201 SPEAR STREET, 3RD FLOOR, SAN FRANCISCO CA 94107
Qvt Associates Gp Llc	10 percent owner	1177 AVENUE OF THE AMERICAS, 9TH FLOOR, NEW YORK NY 10036
Viking Global Performance Llc	10 percent owner	55 RAILROAD AVENUE, 3RD FLOOR, GREENWICH CT 06830
Viking Global Investors Lp	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901